Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET
Company Participants
Neda Safarzadeh – Vice President, Head-Investor Relations, Public Relations and Marketing
Joseph Payne – President and Chief Executive Officer
Andy Sassine – Chief Financial Officer
Pad Chivukula – Chief Scientific Officer and Chief Operating Officer
Conference Call Participants
Yasmeen Rahimi – Piper Sandler
Pete Stavropoulos – Cantor Fitzgerald
Evan Wang – Guggenheim Securities
Carly Kenselaar – Citi
Yanan Zhu – Wells Fargo Securities
Yale Jen – Laidlaw & Company
Operator
Good afternoon, ladies and gentlemen, and welcome to the Arcturus Therapeutics First Quarter 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we’ll conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Tuesday, May 9, 2023.
I would now like to turn the conference over to Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing. Please go ahead.
Neda Safarzadeh
Thank you, operator. Good afternoon, and welcome to Arcturus Therapeutics first quarter 2023 financial update and pipeline progress call. Today’s call will be led by Joseph Payne, our President and CEO; and Andy Sassine, our CFO. Dr. Pad Chivukula, our CSO and COO will join in for the Q&A session as well.
Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance and achievements to differ materially from those expressed or implied by the statements.
Please see the forward-looking statement disclaimer on the company’s press release issued earlier today, as well as the risk factors section in our most recent Form 10-K and in subsequent filings with the SEC.
In addition, any forward-looking statements represent our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements to reflect future information, events or circumstances.
And with that, I’ll now turn the call over to Joe.
Joseph Payne
Thank you, Neda, and good afternoon to all and good evening to our friends on the East Coast. I will begin my remarks by highlighting our ARCT-154 COVID-19 vaccine Phase 3 program. This is our most advanced clinical program. ARCT-154 has the potential to offer effective and longer lasting protection against COVID-19.